Financial Ratios ICON Public Limited Company
Equities
ICLR
IE0005711209
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
145.58 USD | -2.64% |
|
-1.36% | -30.58% |
07-14 | ICON Public Limited Company, Q1 2025 Earnings Call, May 01, 2025 | |
07-09 | Truist Trims Price Target on ICON to $187 From $190, Keeps Buy Rating | MT |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 8.07 | 3.21 | 3.13 | 3.82 | 4.5 | |||||
Return on Total Capital | 11.65 | 4.17 | 4 | 4.93 | 5.8 | |||||
Return On Equity % | 18.98 | 3.09 | 6.1 | 6.9 | 8.44 | |||||
Return on Common Equity | 18.9 | 3.09 | 6.1 | 6.9 | 8.44 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 29.31 | 27.56 | 28.66 | 29.65 | 29.51 | |||||
SG&A Margin | 12.3 | 10.72 | 10.12 | 9.56 | 8.89 | |||||
EBITDA Margin % | 17.01 | 15.49 | 18.54 | 20.09 | 20.62 | |||||
EBITA Margin % | 15.33 | 14.11 | 17.17 | 18.54 | 18.96 | |||||
EBIT Margin % | 14.64 | 9.74 | 11.19 | 12.88 | 14.73 | |||||
Income From Continuing Operations Margin % | 11.9 | 2.79 | 6.53 | 7.54 | 9.56 | |||||
Net Income Margin % | 11.88 | 2.79 | 6.53 | 7.54 | 9.56 | |||||
Net Avail. For Common Margin % | 11.72 | 2.79 | 6.53 | 7.54 | 9.56 | |||||
Normalized Net Income Margin | 8.89 | 3.99 | 5.13 | 5.49 | 7.48 | |||||
Levered Free Cash Flow Margin | 15.38 | 17.07 | 4.91 | 11.76 | 13.21 | |||||
Unlevered Free Cash Flow Margin | 15.65 | 18.92 | 6.53 | 14.15 | 14.72 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.88 | 0.53 | 0.45 | 0.48 | 0.49 | |||||
Fixed Assets Turnover | 10.58 | 13.81 | 14.91 | 16.15 | 16.05 | |||||
Receivables Turnover (Average Receivables) | 2.67 | 3.52 | 3.33 | 2.99 | 3.05 | |||||
Inventory Turnover (Average Inventory) | 494.35 | 749.1 | - | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.87 | 1.19 | 1.2 | 1.21 | 1.26 | |||||
Quick Ratio | 1.82 | 1.14 | 1.15 | 1.16 | 1.21 | |||||
Operating Cash Flow to Current Liabilities | 0.51 | 0.33 | 0.21 | 0.41 | 0.46 | |||||
Days Sales Outstanding (Average Receivables) | 137.02 | 103.55 | 109.74 | 122.07 | 120 | |||||
Days Outstanding Inventory (Average Inventory) | 0.74 | 0.49 | - | - | - | |||||
Average Days Payable Outstanding | 14.53 | 15.1 | 14.28 | 14.94 | 18.74 | |||||
Cash Conversion Cycle (Average Days) | 123.23 | 88.94 | - | - | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 23.44 | 69.99 | 56.83 | 42.62 | 37.84 | |||||
Total Debt / Total Capital | 18.99 | 41.17 | 36.24 | 29.88 | 27.45 | |||||
LT Debt/Equity | 22.12 | 68.68 | 55.67 | 41.03 | 37.14 | |||||
Long-Term Debt / Total Capital | 17.92 | 40.41 | 35.5 | 28.77 | 26.94 | |||||
Total Liabilities / Total Assets | 46.15 | 53.6 | 50.55 | 45.61 | 43.58 | |||||
EBIT / Interest Expense | 31.46 | 2.93 | 3.77 | 3.11 | 5.14 | |||||
EBITDA / Interest Expense | 38.86 | 4.93 | 6.48 | 4.98 | 7.39 | |||||
(EBITDA - Capex) / Interest Expense | 34.93 | 4.41 | 5.86 | 4.56 | 6.68 | |||||
Total Debt / EBITDA | 0.86 | 6.28 | 3.24 | 2.35 | 2.06 | |||||
Net Debt / EBITDA | -0.81 | 5.44 | 3.05 | 2.12 | 1.75 | |||||
Total Debt / (EBITDA - Capex) | 0.95 | 7.01 | 3.59 | 2.56 | 2.27 | |||||
Net Debt / (EBITDA - Capex) | -0.9 | 6.08 | 3.37 | 2.32 | 1.93 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -0.3 | 95.93 | 41.24 | 4.89 | 1.99 | |||||
Gross Profit, 1 Yr. Growth % | -1.71 | 84.24 | 46.88 | 8.53 | 1.5 | |||||
EBITDA, 1 Yr. Growth % | -3.89 | 78.76 | 69.08 | 13.66 | 4.68 | |||||
EBITA, 1 Yr. Growth % | -4.57 | 80.71 | 71.82 | 13.27 | 4.27 | |||||
EBIT, 1 Yr. Growth % | -5.5 | 30.63 | 62.17 | 20.74 | 16.62 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -11.41 | -53.99 | 229.87 | 21.18 | 29.26 | |||||
Net Income, 1 Yr. Growth % | -11.14 | -53.91 | 229.87 | 21.18 | 29.26 | |||||
Normalized Net Income, 1 Yr. Growth % | -6.15 | -11.86 | 81.56 | 12.29 | 38.85 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -9.43 | -63.41 | 172.44 | 20.72 | 28.78 | |||||
Accounts Receivable, 1 Yr. Growth % | 20.36 | 71.85 | 36.78 | 1.98 | -1.97 | |||||
Inventory, 1 Yr. Growth % | 50 | 20.83 | - | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -4.13 | 106.47 | -5.69 | -0.52 | 5.78 | |||||
Total Assets, 1 Yr. Growth % | 18.16 | 406.08 | -1.16 | -1.14 | -0.66 | |||||
Tangible Book Value, 1 Yr. Growth % | 27.07 | -770.42 | -16.36 | -23.47 | -15.09 | |||||
Common Equity, 1 Yr. Growth % | 14.35 | 335.99 | 5.34 | 8.74 | 3.05 | |||||
Cash From Operations, 1 Yr. Growth % | 37.69 | 45.97 | -32.06 | 106.11 | 10.82 | |||||
Capital Expenditures, 1 Yr. Growth % | 0.81 | 129.3 | 51.64 | -1.03 | 19.45 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 63.62 | 112.73 | -59.39 | 151.3 | 14.6 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 61.74 | 131.71 | -51.21 | 127.14 | 6.1 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 3.81 | 39.76 | 66.36 | 21.72 | 3.43 | |||||
Gross Profit, 2 Yr. CAGR % | 2.69 | 34.77 | 64.75 | 26.26 | 4.95 | |||||
EBITDA, 2 Yr. CAGR % | 2.62 | 30.44 | 73.86 | 38.63 | 9.08 | |||||
EBITA, 2 Yr. CAGR % | 3.39 | 32.97 | 80.31 | 67.9 | 34.63 | |||||
EBIT, 2 Yr. CAGR % | 3.03 | 10.49 | 45.55 | 39.93 | 18.66 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 1.58 | -36.16 | 23.19 | 99.93 | 25.15 | |||||
Net Income, 2 Yr. CAGR % | 1.49 | -36 | 23.31 | 99.93 | 25.15 | |||||
Normalized Net Income, 2 Yr. CAGR % | 2.72 | -9.57 | 26.5 | 42.78 | 24.86 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 2.18 | -42.44 | -0.16 | 81.35 | 24.69 | |||||
Accounts Receivable, 2 Yr. CAGR % | 21.28 | 43.82 | 53.32 | 18.11 | -0.01 | |||||
Inventory, 2 Yr. CAGR % | 44.46 | 34.63 | - | - | - | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 27.74 | 40.69 | 39.54 | -3.14 | 2.58 | |||||
Total Assets, 2 Yr. CAGR % | 20.8 | 144.54 | 123.65 | -1.15 | -0.9 | |||||
Tangible Book Value, 2 Yr. CAGR % | 24.82 | 191.87 | 136.8 | -19.99 | -19.39 | |||||
Common Equity, 2 Yr. CAGR % | 16.89 | 123.28 | 114.31 | 7.03 | 5.86 | |||||
Cash From Operations, 2 Yr. CAGR % | 45.41 | 41.77 | -0.42 | 18.33 | 51.13 | |||||
Capital Expenditures, 2 Yr. CAGR % | 2.71 | 55.15 | 86.47 | 22.5 | 8.73 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 49.15 | 83.74 | -7.05 | 1.02 | 69.7 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 47.58 | 90.76 | 6.32 | 5.27 | 55.24 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 16.74 | 28.29 | 40.26 | 42.65 | 14.75 | |||||
Gross Profit, 3 Yr. CAGR % | 3.89 | 24.78 | 38.69 | 43.35 | 17.4 | |||||
EBITDA, 3 Yr. CAGR % | 5.3 | 23.41 | 42.22 | 50.89 | 26.24 | |||||
EBITA, 3 Yr. CAGR % | 5.62 | 24.46 | 44.83 | 54.43 | 43.25 | |||||
EBIT, 3 Yr. CAGR % | 5.78 | 11.44 | 25.56 | 36.76 | 31.68 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 5.76 | -21.99 | 10.37 | 22.52 | 72.88 | |||||
Net Income, 3 Yr. CAGR % | 5.69 | -21.99 | 10.55 | 22.6 | 72.88 | |||||
Normalized Net Income, 3 Yr. CAGR % | 5.82 | -2.45 | 14.08 | 21.57 | 41.46 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 6.23 | -27.44 | -3.35 | 6.36 | 61.8 | |||||
Accounts Receivable, 3 Yr. CAGR % | 20.86 | 36.22 | 41.43 | 33.83 | 11 | |||||
Inventory, 3 Yr. CAGR % | 29.7 | 36.11 | - | - | - | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 16.66 | 49.91 | 23.13 | 24.66 | -0.26 | |||||
Total Assets, 3 Yr. CAGR % | 16.97 | 94.74 | 80.81 | 70.37 | -0.99 | |||||
Tangible Book Value, 3 Yr. CAGR % | 34.24 | 118.6 | 92.43 | 62.51 | -18.39 | |||||
Common Equity, 3 Yr. CAGR % | 15.82 | 81.27 | 73.82 | 70.93 | 5.69 | |||||
Cash From Operations, 3 Yr. CAGR % | 14.03 | 45.6 | 10.94 | 26.91 | 15.77 | |||||
Capital Expenditures, 3 Yr. CAGR % | 4.52 | 24.66 | 53.97 | 50.97 | 21.48 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 14.76 | 69.14 | 11.09 | 29.49 | 5.36 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 14.46 | 72.79 | 21.09 | 36.94 | 5.55 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 12.17 | 26.88 | 34.5 | 25.62 | 24.17 | |||||
Gross Profit, 5 Yr. CAGR % | 4.25 | 16.46 | 24.86 | 25.37 | 24.06 | |||||
EBITDA, 5 Yr. CAGR % | 7 | 17.48 | 28.65 | 29.28 | 27.9 | |||||
EBITA, 5 Yr. CAGR % | 7.48 | 18.06 | 29.57 | 30.28 | 29.11 | |||||
EBIT, 5 Yr. CAGR % | 7.79 | 10.8 | 20.14 | 22.07 | 22.76 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 6.81 | -10.19 | 12.41 | 13.67 | 16.06 | |||||
Net Income, 5 Yr. CAGR % | 6.77 | -10.19 | 12.41 | 13.67 | 16.18 | |||||
Normalized Net Income, 5 Yr. CAGR % | 7.37 | 2.57 | 13.61 | 13.61 | 18.28 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 9.15 | -13.51 | 3.63 | 4.67 | 7.02 | |||||
Accounts Receivable, 5 Yr. CAGR % | 14.44 | 26.42 | 32.92 | 28.66 | 23.11 | |||||
Inventory, 5 Yr. CAGR % | 21.67 | 19.3 | - | - | - | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 11.5 | 29.12 | 25.33 | 25.88 | 14.46 | |||||
Total Assets, 5 Yr. CAGR % | 14.88 | 56.95 | 51.59 | 48.48 | 42.15 | |||||
Tangible Book Value, 5 Yr. CAGR % | 50.84 | 83.58 | 68.46 | 46.23 | 35.87 | |||||
Common Equity, 5 Yr. CAGR % | 19.38 | 53.55 | 48.14 | 46.82 | 42.55 | |||||
Cash From Operations, 5 Yr. CAGR % | 15.27 | 26.18 | 8.02 | 34.01 | 25.54 | |||||
Capital Expenditures, 5 Yr. CAGR % | 0.53 | 17.09 | 26.03 | 23.79 | 33.97 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 19.19 | 44.65 | 5.95 | 37.63 | 31.61 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 19.28 | 46.19 | 11.62 | 41.72 | 33.74 |
- Stock Market
- Equities
- ICLR Stock
- Financials ICON Public Limited Company
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition